source
- Definium's LSD candidate DT120 shows positive Phase 3 results, moving toward FDA submissionDefinium Therapeutics reported positive topline data from its Phase 3 Panorama trial of DT120, an oral LSD formulation for generalized anxiety disorder (GAD). The trial met its primary endpoint, s…
- Public backing fuels FDA hearing on psychedelic therapies and potential COMP360 approvalThe FDA is holding a hearing on Monday to discuss the future of psychedelic drug development, after a wave of public comments expressed strong support for further research. Analysts say the suppor…